Abstract
Model Based Personalised Dosing (MBPD) requires a population pharmacokinetic (PK) or pharmacodynamic model to determine the optimal dose of medication for an individual. Often several models are published, and the decision of which model is implemented in MBPD may have a large impact on its clinical utility. As quoted by Box, “all models are wrong, the practical question is how wrong can they be and still be useful”. Voriconzole, a triazole antifungal and the example used in this manuscript, currently has nine population PK models published. To assess the impact of model-misspecification on MBPD, five structurally mis-specified models for voriconazole were developed. Intensive plasma concentrations were simulated for 100 virtual subjects. The dose adjustments required to reach a target exposure were determined by using the empirical Bayes estimates of the PK parameters under each of the mis-specified models. The predicted plasma concentrations and the probability of clinical outcomes, upon following the dose recommendations, were determined. Models that did not contain non-linear clearance performed poorly, with a median dose recommendation 155–310 mg higher than appropriate doses, when only one plasma concentration was available. Removal of body weight and CYP2C9 genotype as covariates had no clinically significant impact on outcomes. In summary, the removal of important structural components, such as non-linear clearance in the case of voriconazole, had a large impact on the clinical utility of MBPD. The removal of patient covariates, even highly influential covariates such as CYP2C9 genotype for voriconazole, had no clinical impact.
Similar content being viewed by others
References
Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411–59.
Bonate P. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer; 2005.
Han PY, Kirkpatrick CM, Green B. Informative study designs to identify true parameter-covariate relationships. J Pharmacokinet Pharmacodyn. 2009;36(2):147–63.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225–34.
Hicheri Y, Cook G, Cordonnier C. Antifungal prophylaxis in haematology patients: the role of voriconazole. Clin Microbiol Infect. 2012;18 Suppl 2:1–15.
Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(9):4793–9.
Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381–90.
Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother. 2012;18(4):501–7.
Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.
Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21(6):580–6.
Brüggemann RJM, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NMA, Mouton JW, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30(4):403–11.
Wang T, Chen S, Sun J, Cai J, Cheng X, Dong H, et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother. 2014; 69(2):463−70.
Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53(3):935–44.
Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother. 2012;56(1):526–31.
Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother. 2014; 69(6):1633–41.
Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54(10):4424–31.
Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032–42.
Nomura K, Fujimoto Y, Kanbayashi Y, Ikawa K, Taniwaki M. Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 2008;27(11):1141–3.
Han K, Bies R, Johnson H, Capitano B, Venkataramanan R. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clin Pharmacokinet. 2011;50(3):201–14.
McDougall DA, Martin J, Playford EG, Green B. Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. J Pharmacokinet Pharmacodyn. 2016; 43(2):165–77.
Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79(3):241–57.
Wang G, Lei H-P, Li Z, Tan Z-R, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281–5.
Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61(3):174–83.
Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.
Al-Sallami H, Goulding A, Taylor R, Grant A, Williams S, Duffull S. A semi-mechanistic model for estimating fat free mass in children. Population Analysis Group Europe; Athens 2011.
Gilbert DN. The Sanford guide to antimicrobial therapy. Sperryville: Antimicrobial Therapy, Inc; 2011. p. 220.
S B, LB S, A B, RJ B. NONMEM user’s guides. (1989–2009). Ellicott City, MD, USA: Icon Development Solutions; 2009.
R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55(10):4782–8.
Antifungal agents: breakpoint tables for interpretation of MICs. European Committee on Antimicrobial Susceptibility Testing, 2015 2015-11-16. Report No.: Contract No.: 8.0.
Box G, NR D. Emperical model-building and response surgaces. New York, NY: Wiley; 1987.
Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014;44(3):183–93.
Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–63.
Geist MJP, Egerer G, Burhenne J, Mikus G. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother. 2006;50(9):3227–8.
Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204.
ACKNOWLEDGMENTS
D.A.J.M. is supported by an Australian Postgraduate Award.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McDougall, D.A.J., Martin, J., Playford, E.G. et al. The Impact of Model-Misspecification on Model Based Personalised Dosing. AAPS J 18, 1244–1253 (2016). https://doi.org/10.1208/s12248-016-9943-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-016-9943-9